Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
a(h5n2) live attenuated influenza vaccine
- Development stage
- Unknown
- Lead developer
- Government Pharmaceutical Organization
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
A(H5N2) live attenuated influenza vaccine is a nasal spray vaccine containing an attenuated (weakened) form of the A(H5N2) avian influenza virus. It is designed to induce immunity against H5N2 subtype avian influenza in humans. The vaccine uses egg-based technology for production and is administered intranasally as a single 0.5 mL dose. Its mechanism involves stimulating both mucosal and systemic immune responses, including virus-specific cytotoxic T lymphocytes and antibodies, providing protection against H5N2 infection and potentially broader cross-protection against other related subtypes[8][4]. Developed primarily as part of pandemic preparedness efforts, it has undergone Phase 1 and Phase 2 clinical trials demonstrating safety and immunogenicity in humans[8].
- Brand names
- fluvac h5
- Other names
- live attenuated a(h5n2) influenza vaccinelive h5n2 avian influenza vaccine
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on a(h5n2) live attenuated influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on a(h5n2) live attenuated influenza vaccine.